Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Examining the effectiveness of Gateway-an out-of-court community-based intervention to reduce recidivism and improve the health and well-being of young adults committing low-level offences: study protocol for a randomised controlled trial.

Trials·2021

Same author

Development and preliminary evaluation of the Neurofibromatosis Type 1 Adult Quality of Life (NF1-AdQoL) questionnaire.

Clinical and experimental dermatology·2021

Same author

Severe COVID-19 cases with a history of active or latent tuberculosis.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020

Same author

Epidemiology of Adult Uveitis in a Northern Ireland Tertiary Referral Centre.

The Ulster medical journal·2019

Same author

Certain Preliminary Observations on the Treatment of Anæmia by Tryptophan and Histidine.

Glasgow medical journal·2018

Same author

From Landour to the Snowy Range.

The Indian medical gazette·2017

Search research articles

Related Experiment Video

Updated: Jul 25, 2026

Methods for Intravenous Self Administration in a Mouse Model

Methods for Intravenous Self Administration in a Mouse Model

Published on: December 8, 2012

Intravenous cocaine challenges during desipramine maintenance.

T Kosten¹, F H Gawin, D G Silverman

¹Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519.

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology

|November 1, 1992

Summary

Desipramine (DMI) did not alter the cocaine "high" but reduced the desire for cocaine in participants. This suggests DMI may help reduce cocaine craving and its physiological effects.

More Related Videos

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

Published on: June 18, 2018

Related Experiment Videos

Last Updated: Jul 25, 2026

Methods for Intravenous Self Administration in a Mouse Model

Methods for Intravenous Self Administration in a Mouse Model

Published on: December 8, 2012

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

Published on: June 18, 2018

Area of Science:

Pharmacology
Neuroscience
Addiction Medicine

Background:

Cocaine abuse remains a significant public health issue.
Desipramine (DMI) is a tricyclic antidepressant with potential applications in treating substance use disorders.
Understanding DMI's effects on cocaine's subjective and physiological impacts is crucial for treatment development.

Purpose of the Study:

To investigate the effects of desipramine (DMI) maintenance on the subjective and physiological responses to intravenous cocaine challenges.
To assess DMI's potential to reduce cocaine craving and desire.

Main Methods:

A within-subjects design was employed with five participants.
Participants received intravenous challenges of placebo and varying doses of cocaine (0.125-0.5 mg/kg).
These challenges were administered during both placebo and active desipramine (DMI) maintenance (150 mg daily for ≥10 days).

Main Results:

Desipramine (DMI) did not alter the subjective "high" reported after cocaine infusion.
However, DMI significantly attenuated the "desire for cocaine" following a single cocaine dose.
Physiologically, DMI increased baseline heart rate but attenuated the incremental heart rate response to cocaine.

Conclusions:

Laboratory findings suggest desipramine (DMI) may effectively reduce cocaine craving, both during and between episodes of use.
Combined with clinical trial data, DMI shows promise as a therapeutic agent for cocaine abuse.
DMI's physiological effects include blunting the heart rate response to cocaine, indicating a potential mechanism for reducing its cardiovascular impact.